Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer DB Revenue Type — Direct Product Sales by Quarter
DB Revenue Type — Direct Product Sales ($M) ($M)
Pfizer DB Revenue Type — Direct Product Sales: $11,863M in Q2 2026, down 0.8% from a year earlier.
Latest, Q2 2026
11,863
Period ended Jun 28, 2026
Change on a year earlier
-0.8%
11,954 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Database (SEC Form 10-K / 10-Q XBRL via lib/db.py).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Revenue Type — Direct Product Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 11,863 | -0.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 11,715 | +3.7% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 14,495 | -3.9% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 13,920 | -9.7% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 11,954 | +10.0% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 11,294 | -9.2% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 15,085 | +22.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 29, 2024 | 15,417 | +33.1% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 10,871 | +1.0% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 12,443 | -23.3% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 12,339 | – | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 11,587 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jul 2, 2023 | 10,766 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Apr 2, 2023 | 16,221 | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). Pfizer DB Revenue Type — Direct Product Sales ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/db-prod-direct
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.